Effect of Pregabalin on Shoulder Pain in Patients With Central Sensitization After Arthroscopic Rotator Cuff Repair

Launched by THE CATHOLIC UNIVERSITY OF KOREA · Apr 11, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how a medication called Pregabalin can help manage shoulder pain in patients who have had surgery to repair a torn rotator cuff and experience a condition known as central sensitization. Central sensitization can make pain feel more intense and harder to control. The study aims to find out if Pregabalin, taken alongside standard pain medications after surgery, can reduce pain and improve movement and overall well-being for these patients.

To participate, you need to be between 19 and 70 years old and have undergone surgery for a rotator cuff tear, along with having a specific type of pain syndrome related to central sensitization. The trial will involve two groups of patients: one group will receive both standard pain medications and Pregabalin, while the other group will only receive the standard medications. Participants will be monitored for up to a year after their surgery to see how well their pain is managed. This study is not yet recruiting, so no one can join just yet, but it promises to provide valuable information on pain management after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age over 19 to under 70
• • Underwent arthroscopic rotator cuff repair due to a tear of the rotator cuff.
• • Clinical diagnosis of myofascial pain syndrome
• • Central sensitization (Central Sensitization Inventory (CSI) score of 40 or above).
• Exclusion Criteria:
• • Previous history of Pregabalin prescription
• • Hypersensitivity reactions or severe complications after taking Pregabalin.
• • Diagnosed with and are being treated for psychiatric disorders
• • Localized infection, sepsis, or previous neurological abnormalities
• • Uncontrolled hypertension (evidenced by a resting blood pressure of more than 100 mmHg)
• • Liver function abnormalities (aspartate aminotransferase or alanine aminotransferase \>60 IU/litre).
• • major cardiovascular diseases or renal impairments